Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. 1990

L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.

Bombesin-related peptides have a large number of physiological functions as well as having an autocrine growth mechanism for the regulation of small cell lung cancer cells. In the present study we have synthesized 21 des-Met amide or alkylamide analogues of bombesin and compared their abilities to function as bombesin receptor antagonists in guinea pig pancreatic acini and Swiss 3T3 cells with those of the previously most potent antagonist described, [Leu13 psi(CH2NH)Leu14]bombesin (analogue I). All des-Met analogues functioned as antagonists. Bn(1-13)NH2 was approximately equipotent to I (Ki = 60-80 nM) whereas Bn(6-13)NH2 was 30-fold less potent (Ki = 1800 nM). Formation of an ethylamide, Bn(6-13)ethylamide, increased the potency 30-fold such that this octapeptide was equipotent to I. The addition of a D-Phe6 moiety to I did not change potency but caused a 30-fold increase in potency of Bn(6-13)NH2 and a 8-fold increase in the potency of Bn(6-13)ethylamide (Ki = 16 nM). Additional studies of both NH2- and COOH-terminal alterations in Bn(6-13)NH2 demonstrated that the most potent antagonist was [D-Phe6]Bn(6-13)propylamide (PA), having IC50's of 1.6 nM and 0.8 nM for bombesin-stimulated amylase release and Swiss 3T3 cell growth, respectively. Detailed studies of the most potent amide analogue, [D-Phe6]Bn(6-13)NH2, and alkylamide analogue, [D-Phe6]Bn(6-13)PA, demonstrated that these analogues functioned as competitive antagonists and that their action was selective for the bombesin receptor. These results demonstrate that, as with CCK- and gastrin-related peptides, the C-terminal amino acid is important for initiating a biologic response but not essential for determining receptor affinity.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D001839 Bombesin A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function. Bombesin 14,Bombesin Dihydrochloride,Dihydrochloride, Bombesin
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000681 Amylases A group of amylolytic enzymes that cleave starch, glycogen, and related alpha-1,4-glucans. (Stedman, 25th ed) EC 3.2.1.-. Diastase,Amylase
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities

Related Publications

L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
March 1987, The American journal of physiology,
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
January 1991, Growth factors (Chur, Switzerland),
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
August 1996, Regulatory peptides,
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
June 1988, British journal of cancer,
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
June 1992, Farmaco (Societa chimica italiana : 1989),
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
August 1988, Biochemical and biophysical research communications,
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
November 1990, FEBS letters,
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
December 1988, Journal of cellular biochemistry,
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
December 1993, The American journal of physiology,
L H Wang, and D H Coy, and J E Taylor, and N Y Jiang, and S H Kim, and J P Moreau, and S C Huang, and S A Mantey, and H Frucht, and R T Jensen
April 1995, Pancreas,
Copied contents to your clipboard!